Press Room

Press Clipping / Jan 25, 2019

Fire Services Bureau holds emergency drill at Hovione plant in Taipa

Macau News Agency, January 25, 2019

The Fire Services Bureau held an emergency drill at the Hovione pharmaceutical plant in Taipa, to better strengthen the resilience and coordination of the bureau, and about 150 personnel from both parties participated.

Macau Factory | Hovione

Macau (MNA) – The Fire Services Bureau (CB) on Thursday held an emergency drill at the Hovione PharmaScience Ltd Plant (Hovione) in Taipa, to better strengthen the resilience and coordination of the bureau.

According to a release by the CB, the drill simulated an accident occurring when a worker operating a forklift at the pharmaceutical plant pierced a methanol solvent storage tank and caused a fire.

During the evacuation process of the drill, workers pretended to be injured while the remainder of the staff took safety measures in accordance with the internal contingency plan of the plant, and evacuated all relevant personnel to their emergency meeting point.

When informed of the ‘accident’, the CB dispatched nine emergency vehicles and 37 firefighters to the scene who carried out fire fighting, evacuations, search and rescue, as well as caring for the injured, according to an established plan.

The exercise lasted for about an hour, and a total of 150 personnel from both Hovione and the CB participated in the exercise.

The release states that the drill went smoothly and achieved its intended purpose, and after its completion, a meeting took place between both parties to discuss future exercises in testing their responses.

 

Read complete article at MNA

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026